Last, of all, the subcutaneous xenograft model confirmed that TRIM22 depletion led to enhanced in vivo tumor growth, which could be notably inhibited by KAT2A knockdown, as indicated by tumor volume curves and tumor weight (Fig. 4G–I). Here, KAT2A is linked to neoplasm.